Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. (Q31082841)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

phase III clinical trial

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Thomas Blevins

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Francesco Giorgino

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Ryan T Hietpas

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Fady T Botros

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

publication date

15 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

776-790

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Drug-induced hypoglycaemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Circulation and degradation of GIP and GLP-1.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Exenatide-associated ischemic renal failure.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

21 January 2018

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide-induced acute kidney injury

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2810

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.2810

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27102969%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31082841&oldid=1976003727"